Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-aminoisobutyric acid + abscisic acid
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BAIBA + ABA is an oral combination therapy consisting of beta-aminoisobutyric acid (BAIBA) and abscisic acid (ABA). BAIBA is an exercise-induced myokine that promotes the browning of white adipose tissue by upregulating Uncoupling Protein 1 (UCP-1) through Peroxisome Proliferator-Activated Receptor alpha (PPARα) signaling. ABA is a plant hormone that acts as a ligand for the Lanthionine Synthetase C-Like 2 (LANCL2) receptor, stimulating the secretion of Glucagon-Like Peptide-1 (GLP-1). This combination is being investigated as an adjunct to lifestyle modifications for the management of Polycystic Ovary Syndrome (PCOS), particularly in South Asian populations where impaired thermogenesis and incretin signaling are prevalent. Clinical data suggests it effectively reduces body weight, waist circumference, and hyperandrogenic symptoms such as hirsutism and acne.
- Other names
- BAIBA + ABA combination
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)UCP1 (Uncoupling protein 1)GLP1R (GLP-1R)LANCL2 (Lanthionine synthetase C-like protein 2)PPARG (Peroxisome proliferator-activated receptor gamma)LANCL (Lanthionine synthetase C-like protein family)
Beyond the preview
Go deeper on beta-aminoisobutyric acid + abscisic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta-aminoisobutyric acid + abscisic acid.